Scarica l'app Stockscreener
105.18
0.09%
0.09
Dopo l'orario di chiusura:
105.00
-0.18
-0.17%
Precedente Chiudi:
$105.09
Aprire:
$105.06
Volume 24 ore:
3.15M
Relative Volume:
0.93
Capitalizzazione di mercato:
$8.95B
Reddito:
-
Utile/perdita netta:
$-153.72M
Rapporto P/E:
-52.59
EPS:
-2
Flusso di cassa netto:
$-103.81M
1 W Prestazione:
-0.11%
1M Prestazione:
+16.25%
6M Prestazione:
+83.56%
1 anno Prestazione:
+365.19%
Intervallo 1D:
$105.04
$105.25
Intervallo di 1 settimana:
$105.02
$105.31
Portata 52W:
$18.51
$105.50
Verona Pharma Plc Adr Stock (VRNA) Company Profile
Nome
Verona Pharma Plc Adr
Settore
Industria
Telefono
011-44-0-2032834200
Indirizzo
3 MORE LONDON RIVERSIDE, LONDON
Confronta VRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRNA
Verona Pharma Plc Adr
|
105.18 | 8.95B | 0 | -153.72M | -103.81M | -2.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-07-01 | Iniziato | Wolfe Research | Outperform |
| 2025-04-28 | Iniziato | TD Cowen | Buy |
| 2025-04-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-01-10 | Iniziato | ROTH MKM | Buy |
| 2024-10-03 | Iniziato | Wells Fargo | Overweight |
| 2023-05-22 | Ripresa | Jefferies | Buy |
| 2022-09-19 | Ripresa | Wedbush | Outperform |
| 2022-08-26 | Iniziato | Piper Sandler | Overweight |
| 2021-09-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-25 | Iniziato | Jefferies | Buy |
| 2020-08-10 | Iniziato | Canaccord Genuity | Buy |
| 2019-04-18 | Iniziato | BTIG Research | Buy |
Mostra tutto
Verona Pharma Plc Adr Borsa (VRNA) Ultime notizie
Merck Q2: EPS Beats, but Sales Flat as Vaccine Demand Slips Globally - Investing.com
Verona Pharma stock hits all-time high at 105.31 USD By Investing.com - Investing.com Nigeria
Verona Pharma stock hits all-time high at 105.31 USD - Investing.com
Verona Pharma Plc ADR’s Shares Reel: 69.24% Quarterly Revenue Decline Amid 8.93B Market Cap - investchronicle.com
Verona Pharma stock reaches all-time high at 105.0 USD By Investing.com - Investing.com India
Verona Pharma stock reaches all-time high at 105.0 USD - Investing.com Australia
Merck to Acquire Verona Pharma in $10 Billion Deal to Expand Respiratory Drug Portfolio - MSN
Pharmaceutical Stocks To Research – July 12th - Defense World
Top Medical Stocks To Follow Now – July 12th - Defense World
Wells Fargo Downgrades Verona Pharma plcDepositary Receipt () (VRNA) - MSN
Merck stock rises as UBS reiterates Buy rating after Verona Pharma acquisition By Investing.com - Investing.com South Africa
Merck to acquire Verona Pharma stock for $107 per ADS in $10 billion deal By Investing.com - Investing.com South Africa
Verona Pharma stock rating downgraded to Neutral by Roth/MKM after Merck offer - Investing.com South Africa
Merck to Acquire Verona Pharma for $10 Billion in Bid to Cushion "Patent Cliff" Impact - Mitrade
Verona Pharma stock hits all-time high at 104.83 USD By Investing.com - Investing.com South Africa
American pharmaceutical company Merck acquires British Verona Pharma for $10 billion - AKM.RU
Verona Pharma stock hits all-time high at 104.83 USD - Investing.com
Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck - Nasdaq
Merck to acquire Verona Pharma for $10 billion By Investing.com - Investing.com Nigeria
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma - MarketWatch
Merck to acquire Verona Pharma for $10 billion - Investing.com Australia
Can Verona Pharma Plc ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Starbucks, Freeport-McMoran and Verona Pharma rise premarket; WPP, T-Mobile fall By Investing.com - Investing.com South Africa
Merck compra por 10.000 millones de dólares Verona Pharma - Yahoo Finanzas
Best Momentum Stock To Buy For July 7th - Barchart.com
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli - Yahoo Finance
Up 515%, Watch This Biopharma Breakout - inkl
Verona Pharma: A Blockbuster Franchise In The Making - Seeking Alpha
Investing $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Today - Barchart.com
Piper Sandler reiterates Verona Pharma stock rating and target By Investing.com - Investing.com UK
21 Best-Performing Small-Cap Stocks for June 2025 - NerdWallet
Verona Pharma (VRNA) Shares Soar 5.47% to Record High - AInvest
Verona Pharma ADR Surges, Matches Key 52-Week High: What’s Fueling the Rally? - Daily Chhattisgarh News
Verona Pharma stock soars to all-time high of $77.08 By Investing.com - Investing.com Nigeria
FDA Approves GSK's Nucala for Expanded Use in COPD - Zacks Investment Research
Restart of Student Loan Repayments Could Squeeze Consumer Spending and Slow Economic Growth - iHeart
Verona Pharma stock soars to all-time high of $74.36 By Investing.com - Investing.com UK
Market Update: Verona Pharma Plc ADR (VRNA) Sees Negative Movement, Closing at 69.14 - DWinneX
Verona Pharma Plc ADR (NASDAQ: VRNA): An Enticing Stock To Watch - Stocksregister
IBD Stock Of The Day Verona Pharma Tests Buy Point After Earnings Breakout - Investor's Business Daily
Verona Pharma’s general counsel sells shares worth $234,126 By Investing.com - Investing.com India
Verona Pharma director Vikas Sinha sells $178,416 in stock By Investing.com - Investing.com South Africa
Verona Pharma’s general counsel sells shares worth $234,126 - Investing.com
Verona Pharma Plc ADR (VRNA)’s Market Momentum: Closing Strong at 72.07, Down -1.56 - DWinneX
What is Verona Pharma Plc ADR (VRNA) Stock Return on Shareholders’ Capital? - Sete News
Verona Pharma Plc ADR [VRNA] Stock trading around $73.21 per share: What’s Next? - dbtnews.com
VRNA’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Watch this stock’s price performance: Verona Pharma Plc ADR (NASDAQ:VRNA) - uspostnews.com
Verona Pharma ADR earnings beat by $0.05, revenue topped estimates - Investing.com UK
Verona Pharma Plc ADR (NASDAQ: VRNA) Could Soar To Much Higher Prices In Coming Months - Marketing Sentinel
TD Cowen starts Verona Pharma stock at Buy, sets $100 target - Investing.com
Verona Pharma Plc Adr Azioni (VRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Verona Pharma Plc Adr Azioni (VRNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rickard Kathleen A. | Chief Medical Officer |
Jul 07 '25 |
Option Exercise |
0.00 |
86,064 |
0 |
2,632,536 |
| Fisher Andrew | General Counsel |
Jul 07 '25 |
Option Exercise |
0.00 |
86,064 |
0 |
446,063 |
| ZACCARDELLI DAVID | President and CEO |
Jul 07 '25 |
Option Exercise |
0.00 |
229,512 |
0 |
13,419,680 |
| Fisher Andrew | General Counsel |
Jun 16 '25 |
Option Exercise |
2.01 |
80,000 |
160,904 |
439,999 |
| Fisher Andrew | General Counsel |
Jun 16 '25 |
Sale |
11.53 |
80,000 |
922,000 |
359,999 |
| Hahn Mark W | Chief Financial Officer |
Jun 11 '25 |
Sale |
11.40 |
400,000 |
4,560,360 |
12,278,992 |
| ZACCARDELLI DAVID | President and CEO |
Jun 11 '25 |
Sale |
11.40 |
400,000 |
4,560,520 |
13,190,168 |
0.93%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):